GALT

MKT CAP:$156M

Galectin Therapeutics Inc.

Market Cap

$156M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.35-$1.70 (-41.97%)

Apr 24, 2026

Company Details

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 ...

CEO

Joel Lewis

IPO Date

Sep 4, 2002

Website

galectintherapeutics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$31M

EPS (Diluted)

-$0.48

Free Cash Flow

-$24M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 31, 2026

$0EPS -$0.48

Q4 2025

Mar 31, 2026

$0EPS -$0.08

Q3 2025

Nov 14, 2025

$0EPS -$0.13

Q2 2025

Aug 14, 2025

$0EPS -$0.12

Q1 2025

May 15, 2025

$0EPS -$0.15

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$10.0K	-$10M
Q2 22	$0	-$7.0K	-$10M
Q3 22	$0	$0	-$8M
Q4 22	$0	-$8.0K	-$11M
Q1 23	$0	$0	-$10M
Q2 23	$0	$0	-$9M
Q3 23	$0	-$8.0K	-$9M
Q4 23	$0	-$9.0K	-$10M
Q1 24	$0	-$9.0K	-$10M
Q2 24	$0	-$9.0K	-$11M
Q3 24	$0	-$9.0K	-$9M
Q4 24	$0	-$10.0K	-$12M
Q1 25	$0	-$10.0K	-$8M
Q2 25	$0	-$2.0K	-$5M
Q3 25	$0	$0	-$4M
Q4 25	$0	$12.0K	-$3M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$8M	-$8M
Q2 22	-$7M	-$7M
Q3 22	-$8M	-$8M
Q4 22	-$7M	-$7M
Q1 23	-$11M	-$11M
Q2 23	-$10M	-$10M
Q3 23	-$8M	-$8M
Q4 23	-$5M	-$5M
Q1 24	-$12M	-$12M
Q2 24	-$8M	-$8M
Q3 24	-$9M	-$9M
Q4 24	-$13M	-$13M
Q1 25	-$8M	-$8M
Q2 25	-$7M	-$7M
Q3 25	-$4M	-$4M
Q4 25	-$6M	-$6M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+57.3%
Q2 22	—	+17.9%
Q3 22	—	-1.5%
Q4 22	—	+43.2%
Q1 23	—	+4.1%
Q2 23	—	-6.8%
Q3 23	—	+12.9%
Q4 23	—	-10.1%
Q1 24	—	-6.7%
Q2 24	—	+25.4%
Q3 24	—	-1.1%
Q4 24	—	+30.0%
Q1 25	—	-18.1%
Q2 25	—	-59.0%
Q3 25	—	-53.7%
Q4 25	—	-72.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$858.0K	—
Q2 22	$647.0K	—
Q3 22	$681.0K	—
Q4 22	$681.0K	—
Q1 23	$662.0K	—
Q2 23	$0	—
Q3 23	$586.0K	—
Q4 23	$497.0K	—
Q1 24	$604.0K	—
Q2 24	$738.0K	—
Q3 24	$515.0K	—
Q4 24	$590.0K	—
Q1 25	$468.0K	—
Q2 25	$500.0K	—
Q3 25	$496.0K	—
Q4 25	$195.0K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$8M	—	$2M
Q2 22	$8M	—	$2M
Q3 22	$7M	$2M	—
Q4 22	$9M	—	$2M
Q1 23	$9M	$2M	—
Q2 23	$7M	$2M	—
Q3 23	$8M	—	$1M
Q4 23	$8M	—	$1M
Q1 24	$8M	—	$2M
Q2 24	$10M	—	$1M
Q3 24	$8M	—	$1M
Q4 24	$11M	—	$1M
Q1 25	$6M	—	$1M
Q2 25	$3M	—	$1M
Q3 25	$3M	—	$2M
Q4 25	$2M	$1M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$32M	$0	$32M
Q2 22	$24M	$0	$24M
Q3 22	$16M	$0	$16M
Q4 22	$19M	$0	$19M
Q1 23	$18M	$0	$18M
Q2 23	$18M	$0	$18M
Q3 23	$20M	$0	$20M
Q4 23	$26M	$0	$26M
Q1 24	$24M	$0	$24M
Q2 24	$26M	$0	$26M
Q3 24	$27M	$0	$27M
Q4 24	$15M	$0	$15M
Q1 25	$7M	$0	$7M
Q2 25	$14M	$0	$14M
Q3 25	$12M	$0	$12M
Q4 25	$18M	$0	$18M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	59M	+1.4%	+3.9%
Q2 22	59M	+0.1%	+1.8%
Q3 22	59M	+0.0%	+0.2%
Q4 22	59M	+0.1%	+1.5%
Q1 23	59M	+0.1%	+0.2%
Q2 23	60M	+0.2%	+0.3%
Q3 23	60M	+0.2%	+0.5%
Q4 23	60M	+0.8%	+1.2%
Q1 24	62M	+3.0%	+4.2%
Q2 24	62M	+0.4%	+4.4%
Q3 24	62M	+0.1%	+4.3%
Q4 24	63M	+0.7%	+4.3%
Q1 25	63M	+0.7%	+2.0%
Q2 25	63M	+0.4%	+2.0%
Q3 25	64M	+1.2%	+3.1%
Q4 25	64M	-0.5%	+1.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	9
Q2 22	$0	9
Q3 22	$0	9
Q4 22	$0	12
Q1 23	$0	12
Q2 23	$0	12
Q3 23	$0	12
Q4 23	$0	14
Q1 24	$0	14
Q2 24	$0	14
Q3 24	$0	14
Q4 24	$0	15
Q1 25	$0	15
Q2 25	$0	15
Q3 25	$0	15
Q4 25	$0	9

Revenue / Employee